Lixte Biotechnology Holdings Stock Beta
| LIXTW Stock | USD 0.05 0.0003 0.60% |
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Lixte |
Lixte Biotechnology Holdings Company Beta Analysis
Lixte Biotechnology's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Lixte Biotechnology Beta | -0.045 |
Most of Lixte Biotechnology's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Lixte Biotechnology Holdings has a Beta of -0.045. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The beta for all United States stocks is notably higher than that of the company.
Lixte Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Lixte Biotechnology are expected to decrease at a much lower rate. During the bear market, Lixte Biotechnology is likely to outperform the market.
Lixte Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.72 | ||||
| Number Of Shares Shorted | 1.93 K | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 1.08 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 313.86 K | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | (0.95) X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Beta | -0.045 | ||||
| Market Capitalization | 39.49 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.